However, because SIRT7 promotes tumor progression through mechanisms that extend beyond its enzymatic activity, pharmacological inhibition of its catalytic function alone may be insufficient to achieve durable therapeutic effects. The gene discussed is SIRT7; the disease is neoplasm.